Clinical Research Directory
Browse clinical research sites, groups, and studies.
Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment
Sponsor: Catharina Ziekenhuis Eindhoven
Summary
Imiquimod is a good non-invasive treatment option for women with cervical high-grade squamous intraepithelial neoplasia (cHSIL), especially those with a possible (future) pregnancy wish. Complete response to imiquimod occurs in 55-73% of patients, however side-effects of imiquimod are common and can be extensive. Therefore, biomarkers which can predict response to imiquimod therapy are warranted, to increase therapy efficacy and to avoid side effects in patients who will not respond. This prospective, multi-center cohort study aims to validate the potential of immune related biomarkers to predict the clinical response of patients with primary cHSIL to imiquimod, aims to explore the value of these immune biomarkers in recurrent/residual cHSIL to predict treatment responses for imiquimod and aims to explore their potential in spontaneous regression of cHSIL (CIN2).
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
410
Start Date
2022-06-01
Completion Date
2026-12
Last Updated
2023-09-11
Healthy Volunteers
No
Conditions
Interventions
Imiquimod
Imiquimod 5% will be administered in the evening by either a vaginal applicator or administered on a vaginal tampon for three times a week during 16 weeks. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies, and at 6 months after completion of imiquimod therapy with cytology and if indicated histology.
3x vaginal swab for microbiome analysis
A vaginal swab will be taken from all patients at inclusion (before start of imiquimod), at colposcopy 20 weeks after start of imiquimod and at 6 months after completion of imiquimod treatment during follow-up appointment.
Expectative management
Expectative management of CIN 2 when preferred by the patient. Follow-up 6 months after baseline colposcopy with cytology and if indicated histology.
2x vaginal swab for microbiome analysis
A vaginal swab will be taken from all patients at inclusion and at 6 months after inclusion during follow-up appointment.
Locations (15)
Amphia
Breda, Netherlands
Albert Schweitzer Ziekenhuis
Dordrecht, Netherlands
Catharina Ziekenhuis Eindhoven
Eindhoven, Netherlands
Tergooi MC
Hilversum, Netherlands
Medisch Centrum Leeuwarden
Leeuwarden, Netherlands
Leiden Universitair Medisch Centrum
Leiden, Netherlands
Maastricht Universitair Medisch Centrum
Maastricht, Netherlands
Radboudumc
Nijmegen, Netherlands
Erasmus Medisch Centrum
Rotterdam, Netherlands
Franciscus Gasthuis & Vlietland
Rotterdam, Netherlands
HagaZiekenhuis
The Hague, Netherlands
Diakonessenhuis
Utrecht, Netherlands
Máxima MC
Veldhoven, Netherlands
VieCuri Medisch Centrum
Venlo, Netherlands
Isala
Zwolle, Netherlands